ClinicalTrials.gg

Program

axatilimab

Also written as “Axatilimab”, “INCA034176” and “SNDX-6352”.

Its studies are mostly in Bronchiolitis Obliterans Syndrome · Idiopathic Pulmonary Fibrosis · Neoplasm Metastasis · Coronavirus Infections, led by 2 companies.

Furthest: phase 3, since Feb 9, 202412 company-led studies, 7 open or runningNext primary completion: Jan 6, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte76 open or runningphase 3since Feb 9, 2024Feb 9, 2024Jan 6, 2027phase 2 · NCT06843408
Syndax Pharmaceuticals51 open or runningphase 2since Jul 10, 2018Jun 30, 2017none ahead

Also a collaborator on its studies: devpro-biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2017First study: phase 1 study in Neoplasm MetastasisNew to Syndax PharmaceuticalsSyndax Pharmaceuticals · NCT03238027 · 45 enrolled · United States
  2. Jul 10, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeSyndax Pharmaceuticals · NCT03604692 · 41 enrolled · United States
  3. May 29, 2020Phase 2 study in Coronavirus InfectionsSyndax Pharmaceuticals · NCT04415073 · 1 enrolled · United States
  4. Jan 5, 2021Phase 2 study in Bronchiolitis Obliterans SyndromeSyndax Pharmaceuticals · NCT04710576 · 296 planned · United States, Australia, Belgium and more
  5. Nov 9, 2023Phase 2 study in Idiopathic Pulmonary FibrosisSyndax Pharmaceuticals · NCT06132256 · 145 enrolled · Australia, Belgium, Canada and more
  6. Feb 9, 2024Incyte's first study: phase 3 study in Bronchiolitis Obliterans SyndromeNew to IncyteIncyte · NCT06263478 · 21 enrolled · Japan
  7. Apr 25, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06388564 · 130 enrolled · United States, Belgium, Canada and more
  8. Aug 30, 2024Phase 3 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06585774 · 240 planned · United States, Australia, Austria and more
  9. Nov 27, 2024Phase 1 study in Healthy ParticipantsIncyte · NCT06713590 · 72 enrolled · United States
  10. Feb 6, 2025Phase 3 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06821542 · 9 enrolled · Austria, Belgium, Czechia and more
  11. Feb 20, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06843408 · 32 enrolled · China
  12. Aug 8, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT07124078 · 60 planned · United States, Belgium, Germany and more

Ahead

  1. Jan 6, 2027Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06843408
  2. Sep 28, 2027Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06585774
  3. May 31, 2028Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06821542
  4. Jan 31, 2029Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT07124078

TargetBeta

CSF1R →read by rule
“A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R; CSF1R; macrophage-CSFR; M-CSFR; CD115; c-fms), ”NCIt, by rule
“Macrophage colony stimulating factor receptor inhibitor”ChEMBL 37, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
pimicotinibruleAbbisko Caymanphase 314
vimseltinibruleOno Pharmaceuticalphase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07124078Bronchiolitis Obliterans Syndrome · United States, Belgium, Germany and more2RecruitingIncyteJan 31, 202960
NCT06843408Bronchiolitis Obliterans Syndrome · China2Active, not recruitingIncyteJan 6, 202732
NCT06821542Bronchiolitis Obliterans Syndrome · Austria, Belgium, Czechia and more3Active, not recruitingIncyteMay 31, 20289
NCT06713590Healthy Participants · United States1CompletedIncyteJun 6, 202572
NCT06585774Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more3RecruitingIncyteSep 28, 2027240
NCT06388564Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more2Active, not recruitingIncyteOct 1, 2026130
NCT06263478Bronchiolitis Obliterans Syndrome · Japan3Active, not recruitingIncyteAug 6, 202521
NCT06132256Idiopathic Pulmonary Fibrosis · Australia, Belgium, Canada and more2CompletedSyndax PharmaceuticalsAug 27, 2026145
NCT04710576Bronchiolitis Obliterans Syndrome · United States, Australia, Belgium and more2RecruitingSyndax PharmaceuticalsApr 7, 2023296
NCT04415073Coronavirus Infections · United States2TerminatedSyndax PharmaceuticalsJul 13, 20201
NCT03604692Bronchiolitis Obliterans Syndrome · United States2CompletedSyndax PharmaceuticalsAug 12, 202241
NCT03238027Neoplasm Metastasis · United States1CompletedSyndax PharmaceuticalsNov 20, 202045

How it is read

Names in the registry

  • “Axatilimab”, 5 entries
  • “INCA034176”, 5 entries
  • “axatilimab”, 1 entry
  • “SNDX-6352”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.